Immunotherapy has brought significant progress in treating melanoma, but it doesn’t work for everyone. Only around 40% of patients respond well to immune checkpoint blockade therapy, while many others either don’t respond at all or develop resistance over time. Researchers are working hard to understand why this happens and how to improve these outcomes.
A new study introduces a machine learning tool called the Immunotherapy Resistance cell-cell Interaction Scanner, designed to pinpoint the interactions between different cell types in the tumor environment that may be driving resistance to ICB therapy. By focusing on how cells communicate with each other through specific ligand-receptor interactions, the tool aims to provide a clearer understanding of why some tumors resist treatment.
The researchers believe IRIS could offer more accurate predictions of patient response compared to existing methods, while also opening up potential new targets for therapy. This approach represents a step forward in figuring out how to tackle resistance in cancer treatment, using a combination of computational techniques and biological data.